A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3 Years in Subjects With Active Psoriatic Arthritis

Trial Profile

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3 Years in Subjects With Active Psoriatic Arthritis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms FUTURE 3
  • Sponsors Novartis
  • Most Recent Events

    • 16 Jun 2018 Results of pooled data from psoriatic arthritis (FUTURE 1-3 studies, n=1414) and ankylosing spondylitis (MEASURE 1-4 studies, n=1163) exposed to SEC was evaluated at baseline and at Week 12, 16 (AS only), 24 and 52, were presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
    • 16 Jun 2018 Results (n=2049) of pooled analysis of four phase III trials (FUTURE 2, FUTURE 3, FUTURE 4 and FUTURE 5) presented at the 19th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top